查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598386

治疗性卡介苗疫苗市场：按类型、人口统计和最终用户划分 - 全球预测 2025-2030

Therapeutic BCG Vaccine Market by Type (Immune BCG, Therapy BCG), Demographics (Adults, Pediatrics), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年治疗性卡介苗疫苗市值为5,776万美元，预计2024年将达到6,031万美元，复合年增长率为4.50%，预计到2030年将达到7,863万美元。

治疗性卡介苗疫苗最初是为结核病开发的，但也已用于治疗非肌肉层浸润性膀胱癌（NMIBC）并提供针对多种疾病的免疫力，包括糖尿病和其他癌症，其范围正在扩大，包括探索其潜力。卡介苗疫苗的需求源于其免疫调节特性，这可能会增强免疫系统瞄准和破坏癌细胞的能力。卡介苗疫苗在膀胱癌免疫治疗中的应用已有充分记录，新的研究显示其在肿瘤学和自体免疫疾病方面有更广泛的应用。最终用途范围主要包括医院、癌症治疗中心和寻求创新治疗方法的研究机构。影响市场成长的关键因素包括癌症发病率上升、正在进行的研究证实广泛的治疗应用以及医疗保健投资的增加。相反，副作用风险、严格的监管要求以及新兴市场认知度低等挑战构成了障碍。随着研究进展将应用扩展到其他癌症类型和慢性疾病，市场机会就出现了。投资宣传宣传活动并利用与研究机构的伙伴关係关係可以为您带来竞争优势。限制包括 BCG 生产和分销物流的复杂性以及对强大基础设施的需求。需要创新的领域包括开发更复杂的製剂以提高疗效并减少副作用，以及卡介苗与新药物传输技术的整合。市场的性质正在转向精准医疗，重点是客製化治疗解决方案。与生物技术公司的持续研究和合作可能会促进进一步的突破。此外，加强对医疗保健专业人员有关卡介苗疫苗扩大治疗用途的教育也可能加速市场采用和成长。

主要市场统计
基准年[2023] 5776万美元
预计年份 [2024] 6031万美元
预测年份 [2030] 7863万美元
复合年增长率（%） 4.50%

市场动态：揭示快速发展的治疗性卡介苗疫苗市场的关键市场洞察

供需的动态交互作用正在改变治疗性卡介苗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 婴幼儿人口的增加与儿科医疗的发展
    • 高投入研发治疗性卡介苗疫苗
    • 透过疫苗宣传活动提高认识
  • 市场限制因素
    • 缺乏治疗性卡介苗疫苗
  • 市场机会
    • 开发中国家和低度开发国家开拓的市场
    • 联合国加大力度预防结核病
  • 市场挑战
    • 卡介苗疫苗相关的副作用

波特五力：驾驭治疗性卡介苗疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解治疗性卡介苗疫苗市场的外部影响

外部宏观环境因素在塑造治疗性卡介苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解治疗性卡介苗市场的竞争状况

治疗性卡介苗疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵治疗性 BCG 疫苗市场供应商绩效评估

FPNV 定位矩阵是评估治疗性 BCG 疫苗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製治疗性 BCG 疫苗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，治疗性卡介苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 婴儿人口的增加和儿科医疗的进步
      • 大量投资治疗性卡介苗疫苗的研发
      • 透过疫苗宣传活动提高认识
    • 抑制因素
      • 治疗性卡介苗疫苗短缺
    • 机会
      • 开发中国家和最不开发中国家开拓的市场
      • 扩大联合国预防结核病的努力
    • 任务
      • 卡介苗疫苗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章治疗性卡介苗疫苗市场：依类型

  • 免疫卡介苗
  • 卡介苗治疗

第七章依人口统计的治疗性卡介苗疫苗市场

  • 成人
  • 小儿科

第八章治疗性 BCG 疫苗市场：依最终用户分类

  • 诊所
  • 医院

第九章美洲治疗性卡介苗疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区治疗性卡介苗疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲治疗性卡介苗疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AJ Vaccines A/S
  • Bharat Biotech Ltd.
  • Biomed-Lublin SA
  • China National Biotec Group Company Limited
  • Green Signal Bio Pharma Private Limited
  • InterVax Ltd.
  • Japan BCG Laboratory
  • Merck & Co., Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Statens Serum Institut
  • Taj Pharmaceuticals Limited
  • Torlak Institute of Virology
Product Code: MRR-030298DFF712

The Therapeutic BCG Vaccine Market was valued at USD 57.76 million in 2023, expected to reach USD 60.31 million in 2024, and is projected to grow at a CAGR of 4.50%, to USD 78.63 million by 2030.

The therapeutic BCG vaccine, originally developed for tuberculosis, has expanded in scope to include its application in treating non-muscle invasive bladder cancer (NMIBC) and exploring potential roles in modulating the immune response for various diseases, including some forms of diabetes and other cancers. The necessity of the BCG vaccine stems from its immunomodulatory properties, which can potentially enhance the immune system's ability to target and destroy cancer cells, making it vital in cancer treatment where immunotherapy is relevant. Its application in immunotherapy for bladder cancer has been well-documented, and emerging research suggests broader applications in oncology and auto-immune conditions. The end-use scope primarily involves hospitals, cancer treatment centers, and research institutions seeking innovative treatment approaches. Key factors influencing market growth include increasing cancer prevalence, ongoing research substantiating broader therapeutic uses, and rising healthcare investments. Conversely, challenges such as the risk of side effects, stringent regulatory requirements, and limited awareness in emerging markets pose barriers. Market opportunities lie in expanding its application to other cancer types and chronic diseases, driven by advancements in research. Investing in awareness campaigns and leveraging partnerships with research institutions could provide a competitive edge. Limitations include the complexity of BCG production and distribution logistics, which require robust infrastructure. Areas ripe for innovation include developing more refined formulations to enhance efficacy and reduce side effects, as well as integrating BCG with new drug delivery technologies. The nature of the market is transitioning towards precision medicine, emphasizing tailored therapeutic solutions. Continuous research and collaboration with biotech firms could spur further breakthroughs. Enhancing education among healthcare professionals regarding the BCG vaccine's expanded therapeutic uses could also accelerate market adoption and growth.

KEY MARKET STATISTICS
Base Year [2023] USD 57.76 million
Estimated Year [2024] USD 60.31 million
Forecast Year [2030] USD 78.63 million
CAGR (%) 4.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic BCG Vaccine Market

The Therapeutic BCG Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising infant population and growing advancement in the pediatric care
    • High investment in research & development of therapeutic BCG vaccine
    • Increasing awareness through vaccination campaign
  • Market Restraints
    • Lack of therapeutic BCG vaccine
  • Market Opportunities
    • Untapped market in developing and underdeveloped countries
    • Growing initiatives by United Nations (UN) for TB preventions
  • Market Challenges
    • Side effects associated with BCG vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic BCG Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic BCG Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic BCG Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic BCG Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic BCG Vaccine Market

A detailed market share analysis in the Therapeutic BCG Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic BCG Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic BCG Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Therapeutic BCG Vaccine Market

A strategic analysis of the Therapeutic BCG Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic BCG Vaccine Market, highlighting leading vendors and their innovative profiles. These include AJ Vaccines A/S, Bharat Biotech Ltd., Biomed-Lublin S.A., China National Biotec Group Company Limited, Green Signal Bio Pharma Private Limited, InterVax Ltd., Japan BCG Laboratory, Merck & Co., Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Statens Serum Institut, Taj Pharmaceuticals Limited, and Torlak Institute of Virology.

Market Segmentation & Coverage

This research report categorizes the Therapeutic BCG Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Immune BCG and Therapy BCG.
  • Based on Demographics, market is studied across Adults and Pediatrics.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising infant population and growing advancement in the pediatric care
      • 5.1.1.2. High investment in research & development of therapeutic BCG vaccine
      • 5.1.1.3. Increasing awareness through vaccination campaign
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of therapeutic BCG vaccine
    • 5.1.3. Opportunities
      • 5.1.3.1. Untapped market in developing and underdeveloped countries
      • 5.1.3.2. Growing initiatives by United Nations (UN) for TB preventions
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with BCG vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Therapeutic BCG Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Immune BCG
  • 6.3. Therapy BCG

7. Therapeutic BCG Vaccine Market, by Demographics

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Pediatrics

8. Therapeutic BCG Vaccine Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Therapeutic BCG Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Therapeutic BCG Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Therapeutic BCG Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AJ Vaccines A/S
  • 2. Bharat Biotech Ltd.
  • 3. Biomed-Lublin S.A.
  • 4. China National Biotec Group Company Limited
  • 5. Green Signal Bio Pharma Private Limited
  • 6. InterVax Ltd.
  • 7. Japan BCG Laboratory
  • 8. Merck & Co., Inc.
  • 9. Sanofi S.A.
  • 10. Serum Institute of India Pvt. Ltd.
  • 11. Statens Serum Institut
  • 12. Taj Pharmaceuticals Limited
  • 13. Torlak Institute of Virology

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC BCG VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC BCG VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THERAPEUTIC BCG VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THERAPEUTIC BCG VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERAPEUTIC BCG VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC BCG VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY IMMUNE BCG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY THERAPY BCG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. THERAPEUTIC BCG VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. THERAPEUTIC BCG VACCINE MARKET, FPNV POSITIONING MATRIX, 2023